Company research
ProMIS Neurosciences Inc.
CIK 1374339Updated Nov 13, 2026
SecurityPMN · NASDAQ · equity
Name history
AMORFIX LIFE SCIENCES LTD · through Nov 3, 2014
PMN price & chart
Loading TradingView…
NASDAQ:PMN on TradingView ↗About the company
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
In the news
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G/A - filed by GREAT POINT PARTNERS LLC regarding ProMIS Neurosciences Inc.
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
10-Q filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
S-8 filing
4 filing
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 21,458,147Source | 24,510,535Source | 56,693,933Source | 9,509,496Source | 1,409,597Source | 67,411,571Source | 13,646,671Source | 3,548,300Source | 9,182,421Source | 18,911,456Source | 13,619,145Source | 6,924,646Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 321Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 20,838Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 15,399,165Source | 21,536,898Source | 53,429,280Source | 4,510,119Source | 992,463Source | 63,814,345Source | 8,364,301Source | 2,496,973Source | 6,116,556Source | 13,291,167Source | 12,598,146Source | 5,875,796Source |
| Assets, CurrentUSD | 21,458,147Source | 24,510,535Source | 56,693,933Source | 9,509,496Source | 1,409,597Source | 65,612,692Source | 13,646,671Source | 3,548,300Source | 9,182,421Source | 18,911,456Source | 13,619,145Source | 6,903,487Source |
| Prepaid Expense and Other Assets, CurrentUSD | 6,025,931Source | 2,941,279Source | 3,230,900Source | 4,966,326Source | 384,776Source | 1,764,594Source | 5,249,319Source | 1,018,969Source | 3,032,112Source | 5,587,238Source | 988,641Source | 996,682Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 12,270,792Source | 17,237,315Source | 7,294,999Source | 9,892,074Source | 3,686,675Source | 6,693,999Source | 4,174,940Source | 3,471,201Source | 10,441,013Source | 2,423,280Source | 9,865,849Source | 8,272,418Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 129,290,671Source | 98,093,270Source | 200,150,367Source | 108,140,611Source | 97,818,797Source | 199,739,348Source | 107,877,891Source | 97,549,317Source | 129,518,812Source | 107,546,433Source | 97,590,426Source | 79,101,061Source |
| Retained Earnings (Accumulated Deficit)USD | -119,732,132Source | -90,448,866Source | -150,380,249Source | -108,152,005Source | -99,724,691Source | -138,650,592Source | -98,034,976Source | -97,101,034Source | -130,406,220Source | -90,687,073Source | -93,465,946Source | -80,253,464Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -371,184Source | -195,369Source |
| Stockholders' Equity Attributable to ParentUSD | 9,187,355Source | 7,273,220Source | 49,398,934Source | -382,578Source | -2,277,078Source | 60,717,572Source | 9,471,731Source | 77,099Source | -1,258,592Source | 16,488,176Source | 3,753,296Source | -1,347,772Source |
| Liabilities and EquityUSD | 21,458,147Source | 24,510,535Source | 56,693,933Source | 9,509,496Source | 1,409,597Source | 67,411,571Source | 13,646,671Source | 3,548,300Source | 9,182,421Source | 18,911,456Source | 13,619,145Source | 6,924,646Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 12,211,047Source | 2,635,087Source | 7,217,744Source | 9,824,087Source | 3,171,956Source | 6,614,619Source | 4,056,248Source | 2,645,914Source | 10,411,831Source | 2,218,425Source | 9,349,662Source | 6,413,044Source |
| Accounts Payable, CurrentUSD | 4,211,485Source | 1,575,235Source | 1,793,475Source | 2,780,179Source | 2,015,167Source | 1,716,823Source | 1,200,162Source | 1,403,592Source | 2,543,415Source | 1,737,463Source | 7,843,136Source | 2,975,398Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 7,999,562Source | 1,059,852Source | 5,424,269Source | 7,043,908Source | 1,156,789Source | 4,897,796Source | 2,856,086Source | 1,242,322Source | 7,868,416Source | 480,962Source | 1,506,526Source | 3,437,646Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Short-term InvestmentsUSD | 33,051Source | 32,358Source | 33,753Source | 33,051Source | 32,358Source | 33,753Source | 33,051Source | 32,358Source | 33,753Source | 33,051Source | 32,358Source | 31,009Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -8,244,372Source | -7,347,903Source | -39,719,147Source | 2,778,873Source | -13,212,482Source | -18,062,263Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 189,425Source | 245,295Source | 857,628Source | 825,808Source | 271,542Source | 487,630Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -826,591Source | -537,301Source | 805,952Source | -6,105,673Source | 4,963,218Source | 2,675,693Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -12,383,520Source | -4,926,866Source | -28,118,579Source | -27,182,095Source | -10,843,676Source | -17,033,883Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -702Source | -693Source | -1,349Source | -1,981Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 1,981Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 70,081,309Source | — | 20,944,670Source | 27,875,809Source | 17,748,800Source | 6,494,654Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 57,697,789Source | -4,926,866Source | -7,174,611Source | 693,021Source | 6,722,350Source | -11,068,109Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 15,399,165Source | 21,536,898Source | 53,429,280Source | 4,510,119Source | 63,814,345Source | 8,364,301Source | 6,116,556Source | 13,291,167Source | 12,598,146Source | 5,875,796Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | — | 76,775Source | — | 87,069Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 197,147Source | 121,036Source | 408,895Source | 212,015Source | 189,425Source | 245,295Source | 857,628Source | 825,808Source | 271,542Source | 487,630Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | — | 241,854Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 20,838Source | 5,072Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | — | — | 321Source | 6,144Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 1,817Source | -305,407Source |
| General and Administrative ExpenseUSD | — | — | 1,953,014Source | 1,870,903Source | 2,744,606Source | 1,434,877Source | 1,673,890Source | 1,995,845Source | 6,787,987Source | 6,189,502Source | 6,379,568Source | 7,292,744Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,580,126Source | 9,275,825Source | -11,729,656Source | -10,117,029Source | -8,244,372Source | -7,347,903Source | -39,719,147Source | 2,778,873Source | -13,212,482Source | -18,062,263Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,580,126Source | 9,275,825Source | -11,729,656Source | -10,117,029Source | -8,244,372Source | -7,347,903Source | -39,719,147Source | 2,778,873Source | 13,212,482Source | 18,062,263Source |
| Nonoperating Income (Expense)USD | — | — | 170,306Source | 13,710,502Source | — | 67,632Source | — | 112,192Source | 448,161Source | 19,606,351Source | 1,050,251Source | 5,317,649Source |
| Operating ExpensesUSD | — | — | 11,750,432Source | 4,434,677Source | 12,266,399Source | 10,184,661Source | 8,644,895Source | 7,460,095Source | 40,167,308Source | 16,827,478Source | 14,262,733Source | 23,379,912Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 536,743Source | 67,632Source | 400,523Source | 112,192Source | 442,569Source | 626,184Source | 384,903Source | 115,525Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 708,468Source | 190,274Source | — | 4,974,253Source |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | — | — | — | — | — | 5,592Source | 22,581,477Source | — | 2,550,877Source |
| InterestExpenseNonoperating | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -11,750,432Source | -4,434,677Source | -12,266,399Source | -10,184,661Source | -8,644,895Source | -7,460,095Source | -40,167,308Source | -16,827,478Source | -14,262,733Source | -23,379,912Source |
| Other Nonoperating Income (Expense)USD | — | — | — | — | 536,743Source | 67,632Source | 400,523Source | 112,192Source | 442,569Source | 626,184Source | 384,903Source | 115,525Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -11,580,126Source | 9,275,825Source | -11,729,656Source | -10,117,029Source | -8,244,372Source | -7,347,903Source | -39,719,147Source | 2,778,873Source | -13,212,482Source | -18,062,263Source |
| Earnings Per Share, BasicUSD per share | — | — | — | — | -1.28Source | -7.26Source | -1.26Source | -5.27Source | -22.61Source | 0.11Source | -1.07Source | -2.41Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | — | -1.28Source | -7.26Source | -1.26Source | -5.27Source | -22.61Source | 0.11Source | -1.07Source | -2.41Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | — | 9,142,366Source | 1,394,048Source | 6,527,779Source | 1,394,048Source | 1,756,844Source | 25,919,965Source | 12,292,707Source | 7,502,609Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | — | 9,142,366Source | 1,394,048Source | 6,527,779Source | 1,394,048Source | 1,756,844Source | 26,461,731Source | 12,292,707Source | 7,502,609Source |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 20,838Source | 5,072Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | — | — | 1,817Source | -305,407Source |
| General and Administrative ExpenseUSD | — | — | 1,953,014Source | 1,870,903Source | 2,744,606Source | 1,434,877Source | 1,673,890Source | 1,995,845Source | 6,787,987Source | 6,189,502Source | 6,379,568Source | 7,292,744Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 282,064Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,580,126Source | 9,275,825Source | -11,729,656Source | -10,117,029Source | -8,244,372Source | -7,347,903Source | -39,719,147Source | 2,778,873Source | 13,212,482Source | 18,062,263Source |
| Nonoperating Income (Expense)USD | — | — | 170,306Source | 13,710,502Source | — | 67,632Source | — | 112,192Source | 448,161Source | 19,606,351Source | 1,050,251Source | 5,317,649Source |
| Operating ExpensesUSD | — | — | 11,750,432Source | 4,434,677Source | 12,266,399Source | 10,184,661Source | 8,644,895Source | 7,460,095Source | 40,167,308Source | 16,827,478Source | 14,262,733Source | 23,379,912Source |
| Research and Development ExpenseUSD | — | — | 9,797,418Source | 2,563,774Source | 9,521,793Source | 8,749,784Source | 6,971,005Source | 5,464,250Source | 33,379,321Source | 10,637,976Source | 7,883,165Source | 16,087,168Source |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-294610
Registration 333-294408
Filing attachments
pmn-ex99d1.htm · 8-K · 2026-11-12
Exhibit 99.1 ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────…
Read attachment ↗pmn-ex99d1.htm · 8-K · 2026-11-12
Exhibit 99.1 Targeting underlying causes of neurodegenerative diseases Copyright 2026, ProMIS Neurosciences Inc., Non-confidential L E G A L D I S C L O S U R E S Forward-Looking Statements & Disclaimers This slide deck may contain certain forward-looking information and “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such information involves known and unknown risks, uncertainties and ot…
Read attachment ↗pmn-20260813xex99d1.htm · 8-K · 2026-08-13
EX-99.1 2 pmn-20260813xex99d1.htm EX-99.1 Exhibit 99.1 ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes. ─────────…
Read attachment ↗pmn-20260728xex99d1.htm · 8-K · 2026-07-28
EX-99.1 2 pmn-20260728xex99d1.htm EX-99.1 Exhibit 99.1 ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) - ProMIS Neuroscie…
Read attachment ↗pmn-20260728xex99d2.htm · 8-K · 2026-07-28
EX-99.2 3 pmn-20260728xex99d2.htm EX-99.2 Exhibit 99.2 PRECISE-AD PMN310 · PHASE 1b BLINDED 6-MONTH INTERIM ANALYSIS Safety & Biomarker Assessment Update Blinded Interim Analysis Topline results expected Q1 2027 1 ──────────────────────────────────────── LEGAL DISCLOSURES Forward-Looking Statements & Disclaimers Blinded Interim Analysis Topline results expected Q1 2027 This slide deck may contain certain forward-looking information and “forward-looking statements” th…
Read attachment ↗pmn-20260512xex99d1.htm · 8-K · 2026-05-12
EX-99.1 2 pmn-20260512xex99d1.htm EX-99.1 Exhibit 99.1 ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights Company closed PIPE financing with gross proceeds of up to $175 million, including the possible exercise of warrants, from long-term global investors. Proceeds are expected to fund the Company through 2027, including completion of the ongoing Phase 1b clinical trial in Alzheimer's disease (AD). PRECISE-AD Phase 1b trial is fully e…
Read attachment ↗